CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics, Inc. (PTI), a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, announced today that it has entered into a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to research, develop and commercialize therapies to treat patients with the most common cystic fibrosis mutation, Delta F508.
